Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
Extraordinary outcomes are built on curiosity, creativity, and the relentless pursuit of smarter healthcare for all. Our breakthroughs power our solutions, supporting the needs of our partners – and their patients.
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
Extraordinary outcomes are built on curiosity, creativity, and the relentless pursuit of smarter healthcare for all. Our breakthroughs power our solutions, supporting the needs of our partners – and their patients.
Impacto sobre el mercado farmacéutico de la OPR SND/1121/2020 Noviembre 2020
La aplicación de la OPR SND/1121/2020 supondrá un impacto de 34M€ sobre el mercado actual, 15M€ menos del estimado en base al proyecto de OPR publicado en septiembre 2020